Danielle N. Margalit MD
Head & Neck
Associate Professor of Radiation Oncology, Harvard Medical School Staff Physician, Dana-Farber Cancer Institute and Brigham and Women's Hospital
Join to View Full Profile
450 Brookline AveBoston, MA 02215
Phone+1 617-632-3591
Dr. Margalit is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Radiation Oncology, 2007 - 2011- Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Radiation Oncology, 2006 - 2010
- Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2006 - 2007
Harvard Medical SchoolClass of 2006
Certifications & Licensure
MA State Medical License 2008 - 2026
ME State Medical License 2020 - 2025
American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
Publications & Presentations
PubMed
- Paranasal Sinus and Nasal Cavity Cancers: Systematic Review and Executive Summary of the American Radium Society Appropriate Use Criteria.Matthew E Witek, Matthew C Ward, Richard Bakst, Ravi A Chandra, Steven Shih-Wei Chang
Head & Neck. 2025-05-09 - 4 citationsA Prospective Trial of Biomarker-Guided Surveillance for HPV-Positive Oropharynx Cancer Using Plasma Tumor Tissue-Modified Viral HPV DNA.Eleni M Rettig, Jonathan D Schoenfeld, Julianna Miller, Bethany Sargent, Evan Carey
Clinical Cancer Research. 2025-05-01 - In Reply to Gregoire et al.Danielle N Margalit, David J Sher
Practical Radiation Oncology. 2025-03-28
Press Mentions
Study Finds Standard Chemoradiation Therapy Superior to Deintensification Approaches for HPV-Related Oropharyngeal CancerApril 1st, 2025- Trial “Informs Practice Tremendously” for Low-Risk HPV-Oropharyngeal CancerOctober 8th, 2024
- Standard Chemoradiation Remains Superior for HPV-Associated Oropharyngeal CancerOctober 4th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
